We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$484M
AUM Growth
+$55.1M
Cap. Flow
+$73.1M
Cap. Flow %
15.11%
Top 10 Hldgs %
57.22%
Holding
53
New
11
Increased
11
Reduced
16
Closed
15
Avg Time Held Equity + Options
4.3 quarters
Top 10 Avg Time Held Equity + Options
4.3 quarters
Top 20 Avg Time Held Equity + Options
4.5 quarters
Avg Time Held Equity only
4.3 quarters
Top 10 Avg Time Held Equity only
4.3 quarters
Top 20 Avg Time Held Equity only
4.5 quarters

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$21.8M
2
BBIO icon
BridgeBio Pharma
BBIO
+$15.4M
3
ROIV icon
Roivant Sciences
ROIV
+$14M
4
DXCM icon
DexCom
DXCM
+$13.1M
5
IMVT icon
Immunovant
IMVT
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.58%
2 Industrials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
TWST icon
51
Twist Bioscience
TWST
$10B
– –
-75,000
Closed -$2.11M –
VRTX icon
52
Vertex Pharmaceuticals
VRTX
$123B
– –
-20,500
Closed -$8.03M –
ACTU icon
53
Actuate Therapeutics
ACTU
$11.2M
– –
-885
Closed -$5.92K –

Similar funds

Prosight Management's Q4 2025 Portfolio in Review

As of Q4 2025, Prosight Management held 53 positions worth $484M, up 13% from $429M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Prosight Management deployed $73.1M of net new capital in Q4 2025, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Nektar Therapeutics: 554,633 shares worth $23.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $15.4M trimmed.

  • Prosight Management's largest Q4 2025 buy was Nektar Therapeutics: 554,633 shares worth $23.4M.
  • Prosight Management added most to Procept Biorobotics in Q4 2025, an estimated $43.2M increase.
  • Prosight Management's biggest Q4 2025 reduction was BridgeBio Pharma, cutting an estimated $15.4M.
  • Prosight Management fully exited Intuitive Surgical in Q4 2025, selling an estimated $21.8M.
  • Prosight Management's ten largest holdings make up 57% of its $484M portfolio in Q4 2025.
  • Prosight Management opened 11 new positions and closed 15 in Q4 2025.
  • Prosight Management's portfolio value rose 13% quarter-over-quarter to $484M.

Based on Prosight Management's 13F filing for Q4 2025, filed 13 Feb 2026.